Skip to content

Research on Influencing Factors and Strategy Optimization of Standardized Anticoagulation in Patients with Atrial Fibrillation in China

Research on Influencing Factors and Strategy Optimization of Standardized Anticoagulation in Patients with Atrial Fibrillation in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112674
Enrollment
Unknown
Registered
2025-11-18
Start date
2025-11-18
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation

Interventions

Phase One: Atrial Fibrillation Observation Group:None
Phase Two: Patient Observation Group:None
Phase Two: Doctor Observation Group:None

Sponsors

Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Phase One 1. Age >=18 years old; 2. Atrial fibrillation records have been confirmed by 12-lead electrocardiogram, pacemaker /ICD electrocardiogram or ambulatory electrocardiogram Phase Two Representative patients with low-risk and high-risk atrial fibrillation were selected from doctors and patients in both the standardized and unstandardized anticoagulation groups. The corresponding medical staff are required to have worked in the local hospital from January 1, 2018 to December 31, 2022. All interviewees should be able to cooperate in completing the data collection of the interviews and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Phase One 1. Combined with rheumatic or moderate to severe mitral stenosis; 2. Combined mechanical valve implantation; 3. Those who have previously received ablation treatment or are scheduled to undergo ablation treatment upon admission this time; 4. Previously received left atrial appendage occlusion treatment or planned to undergo left atrial appendage occlusion treatment upon admission this time; Phase Two: None

Design outcomes

Primary

MeasureTime frame
Anticoagulation standardized or not;

Countries

China

Contacts

Public ContactZhe Zheng

Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

zhengzhe@fuwai.com+86 10 88396051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026